Blue Rock Wealth Management’s Mereo BioPharma MREO Stock Holding History

Blue Rock Wealth Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,000	Closed	-$6.27K	–	117
2026 Q1	$6.27K	Hold	19,000	–	–	﹤0.01%	103
2025 Q4	$7.92K	Sell	19,000 -18,000	-49%	-$34.3K	﹤0.01%	105
2025 Q3	$76.2K	Hold	37,000	–	–	0.05%	104
2025 Q2	$100K	Buy	+37,000	New	+$89.3K	0.07%	100

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Blue Rock Wealth Management's MREO Position: Q2 2026 in Review

Blue Rock Wealth Management sold out of Mereo BioPharma (MREO) in Q2 2026, closing a stake of 19,000 shares — an estimated $6.27K sold.

Blue Rock Wealth Management first reported a position in MREO in Q2 2025 and held it in 4 quarters. The position peaked at $100K in Q2 2025. 60 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Blue Rock Wealth Management reported no remaining Mereo BioPharma position as of Q2 2026 after selling out during the quarter.
Blue Rock Wealth Management sold 19,000 Mereo BioPharma shares in Q2 2026, an estimated $6.27K.
Blue Rock Wealth Management first reported a position in Mereo BioPharma in Q2 2025 and held it in 4 quarters.
Blue Rock Wealth Management's Mereo BioPharma position peaked at $100K in Q2 2025.
60 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Blue Rock Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.